Ursodeoxycholic acid for primary biliary cirrhosis

Area of Science:

• Hepatology
• Autoimmune Diseases
• Clinical Pharmacology

Background:

• Primary biliary cirrhosis (PBC) is a rare autoimmune liver disease with limited effective treatment options.
• Ursodeoxycholic acid (UDCA) has been investigated for its potential therapeutic effects in PBC.
• Randomized clinical trials (RCTs) have explored UDCA's efficacy, but results require synthesis.

Purpose of the Study:

• To evaluate the beneficial and adverse effects of oral ursodeoxycholic acid (UDCA) compared to placebo or no intervention in patients with primary biliary cirrhosis (PBC).
• To systematically review the existing evidence from randomized clinical trials on UDCA for PBC treatment.

Main Methods:

• A comprehensive search of multiple electronic databases (Cochrane Hepato-Biliary Group, MEDLINE, EMBASE) was conducted up to April 2001.
• Included were RCTs assessing peroral UDCA at any dose versus placebo/no intervention in diagnosed PBC patients, prioritizing adequate randomization methods.
• Methodological quality was assessed using Jadad-scores, and outcomes included mortality, liver transplantation, symptoms, biochemistry, and adverse events, analyzed via intention-to-treat.

Main Results:

• Sixteen RCTs involving 1422 patients were analyzed; 15 compared UDCA to placebo.
• UDCA did not significantly impact mortality, liver transplantation (initially), pruritus, fatigue, or quality of life.
• However, UDCA significantly reduced ascites, jaundice, and biochemical markers (serum bilirubin, liver enzymes), and showed a significant effect on reducing liver transplantation incidence (OR=0.68).

Conclusions:

• Ursodeoxycholic acid (UDCA) demonstrates a marginal therapeutic benefit for primary biliary cirrhosis (PBC).
• UDCA is associated with a low incidence of adverse events.
• The overall clinical utility and widespread use of UDCA for PBC require further critical assessment.